LY 2109761
- Catalog NO.:A853576
- CAS No. : 700874-71-1
- Molecular Formula:C26H27N5O2
- Molecular Weight: 441.52
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Product Details
CAS Number | 700874-71-1 | Appearance | White powder |
Catalog Number | A853576 | MDL Number | MFCD12923354 |
Molecular Formula | C26H27N5O2 | Molecular Weight | 441.52 |
Boiling Point | 640.9±55.0°C at 760 mmHg | Melting Point | |
Flash Point | Density | ||
Synonyms | 4-[5,6-Dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]quinoline | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram | |||
Signal Word | Warning | UN Number | |
Hazard Statements | H302;H315;H319;H335 | Class | |
Precautionary Statements | P261;P305+P351+P338 | Packing Group |
Description
LY2109761 is a novel transforming growth factor beta receptor type I and type II dual inhibitor. The effect of LY2109761 has been evaluated on soft agar growth, migration, invasion using a fibroblast coculture model, and detachment-induced apoptosis (anoikis) by Annexin V flow cytometric analysis. The efficacy of LY2109761 on tumor growth, survival, and reduction of spontaneous metastasis have been evaluated in an orthotopic murine model of metastatic pancreatic cancer expressing both luciferase and green fluorescence proteins (L3.6pl/GLT). In vivo, LY2109761 , in combination with gemcitabine, significantly reduced the tumor burden, prolonged survival, and reduced spontaneous abdominal metastases. |